Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 76

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 76
---
 representatives of Citi and Wachtell Lipton in
attendance. Mr. Farrell described the emails he had received from Party A and Party B and, following a discussion by the Board, the Board determined that Mr. Farrell should respond to Party A and Party B prior to signing a transaction with
Alcon, but that the Company should not delay or risk the proposed transaction with Alcon based on the vague communications received from Party A and Party B, noting that such parties would have the ability to make an unsolicited proposal for the
Board’s consideration in the post-signing period. The Board also discussed the fact that Broadwood had indicated it would likely not support, and would consider taking actions to prevent, an acquisition by Alcon, and potential responses STAAR
could take in response, including whether to adopt a stockholder rights plan. Representatives of Wachtell Lipton described the proposed terms of the merger agreement and the transaction, including the “window-shop” provision, termination
fees, and Alcon’s regulatory efforts covenant. Representatives from Citi then reviewed with the Board preliminary financial information relating to STAAR and their preliminary financial analysis, based on the Projections.

On August 4, 2025, the Board met with members of STAAR’s management with representatives of Citi and Wachtell Lipton in attendance.
Representatives of Wachtell Lipton updated the Board regarding certain terms of the proposed merger agreement that had evolved since the Board’s prior meeting on August 3, 2025, and guided the Board in a discussion and review of the
merger agreement, including the interim operating covenants,

-46-

non-solicitation provision, regulatory efforts, conditions to closing, termination rights and termination fees. Representatives from Citi then reviewed
Citi’s financial analysis with respect to fairness, from a financial point of view, to the holders of common stock of the proposed merger consideration of $28.00 per share, based on the Projections, and delivered to the Board an oral opinion,
which was subsequently confirmed by delivery of a written opinion on August 4, 2025, that, as of such date and based upon and subject to the factors and assumptions set forth in its written opinion, the merger consideration of $28.00 in cash
per share of STAAR common stock to be received by STAAR’s stockholders in the merger pursuant to the merger agreement was fair, from a financial point of view, to such holders. For more information, see